•  
  •  
  •  
  •  

2026-04-20 05:13:05

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • MCX to Launch India's First Dedicated Coal Exchange; Receives SEBI Nod
  • Karur Vysya Bank Announces Revision in Lending Rates
  • Arisinfra Solutions Ltd secures order worth Rs. 5.45 crores
  • ICICI Bank Limited Reports Audited Financial Results for FY 2025-26
  • HDFC Bank Limited Reports Strong Annual Performance for FY 2025-26

Keywords Selected:  INE901L01018

Stock Report

  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Methotrexate Injection USP
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Dapagliflozin Tablets, 5 mg and 10 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Paroxetine Extended-Release Tablets USP, 12.5 mg
  • Alembic Pharmaceuticals Achieves First US Prescription Sale of PivyaĀ® Antibiotic
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Lamotrigine Orally Disintegrating Tablets USP, 25 mg, 50 mg, 100 mg and 200 mg
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Efinaconazole Topical Solution, 10%
  • Alembic Pharmaceuticals Ltd receives 2 observations for Karakhadi Injectable Facility
  • Alembic Pharmaceuticals gets USFDA nod for generic Parkinson's disease treatment tablets
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Travoprost Ophthalmic Solution USP, 0.004%
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension, 0.5%/0.3%
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval Dexlansoprazole Delayed Release Capsules, 30 mg and 60 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Sumatriptan Injection USP, 4 mg/0.5 mL and 6 mg/0.5 mL, Single-Dose Autoinjector System
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Triamcinolone Acetonide Injectable Suspension USP, 40 mg/mL
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Paroxetine Extended Release Tablets USP, 25 mg and 37.5 mg.
  • Alembic Pharmaceuticals Ltd receives EIR from USFDA for facility at Panelav
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Phytonadione Injectable Emulsion USP, 1 mg/0.5 mL Single-Dose Prefilled Syringe
  • Alembic Pharmaceuticals Limited receives USFDA Final Approval for Macitentan Tablets, 10mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Carbamazepine Extended-Release Tablets USP, 100 mg, 200 mg, and 400 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) Single-Dose Vials
  • Alembic Pharmaceuticals Ltd receives EIR from USFDA for API-III facility at Karakhadi
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Amlodipine and Atorvastatin Tablets USP
  • Alembic Pharmaceuticals receives USFDA Final Approval for Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg and 20 mg

Latest Post

  • MCX to Launch India's First Dedicated Coal Exchange; Receives SEBI Nod
  • Karur Vysya Bank Announces Revision in Lending Rates
  • Arisinfra Solutions Ltd secures order worth Rs. 5.45 crores
  • ICICI Bank Limited Reports Audited Financial Results for FY 2025-26
  • HDFC Bank Limited Reports Strong Annual Performance for FY 2025-26


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025